Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Artios Pharma Ltd was established in May 2016 to develop a next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy. Cancers change their DDR pathways to allow mutations in their DNA so that they can evolve and adapt. This is what causes cancers to overcome many current therapies. Targeting the remaining DDR pathways has been proven to selectively kill cancer cells through a conc...
Artios Pharma Ltd was established in May 2016 to develop a next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy. Cancers change their DDR pathways to allow mutations in their DNA so that they can evolve and adapt. This is what causes cancers to overcome many current therapies. Targeting the remaining DDR pathways has been proven to selectively kill cancer cells through a concept known as ‘synthetic lethality’. This has been demonstrated with the recent success of PARP inhibitors such as Lynparza™ (olaparib; AstraZeneca) in treating a number of cancer types.

List your booth number for exhibitions, ask us